APA (7th ed.) Citation

FV, A., EJ, T., KM, A., NS, K., HF, W., SE, F., & RM, C. (1996). Clinical Benefit within Patient Subgroups Receiving c7E3 Fab (Abciximab) During Percutaneous Coronary Revascularization: Subgroup Analysis from the EPIC Trial. The Journal of invasive cardiology, 8 Suppl B, 21B.

Chicago Style (17th ed.) Citation

FV, Aguirre, Topol EJ, Anderson KM, Kleiman NS, Weisman HF, FitzPatrick SE, and Califf RM. "Clinical Benefit Within Patient Subgroups Receiving C7E3 Fab (Abciximab) During Percutaneous Coronary Revascularization: Subgroup Analysis from the EPIC Trial." The Journal of Invasive Cardiology 8 Suppl B (1996): 21B.

MLA (9th ed.) Citation

FV, Aguirre, et al. "Clinical Benefit Within Patient Subgroups Receiving C7E3 Fab (Abciximab) During Percutaneous Coronary Revascularization: Subgroup Analysis from the EPIC Trial." The Journal of Invasive Cardiology, vol. 8 Suppl B, 1996, p. 21B.